1. Home
  2. STAA vs DVAX Comparison

STAA vs DVAX Comparison

Compare STAA & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STAAR Surgical Company

STAA

STAAR Surgical Company

HOLD

Current Price

$25.58

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation

HOLD

Current Price

$10.94

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STAA
DVAX
Founded
1982
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
STAA
DVAX
Price
$25.58
$10.94
Analyst Decision
Hold
Buy
Analyst Count
8
4
Target Price
$22.50
$26.50
AVG Volume (30 Days)
762.7K
1.7M
Earning Date
11-05-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$230,591,000.00
$330,514,000.00
Revenue This Year
N/A
$24.63
Revenue Next Year
$22.61
$15.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
26.73
52 Week Low
$13.50
$9.20
52 Week High
$30.81
$14.63

Technical Indicators

Market Signals
Indicator
STAA
DVAX
Relative Strength Index (RSI) 44.70 50.47
Support Level $25.55 $10.79
Resistance Level $26.93 $11.10
Average True Range (ATR) 0.92 0.31
MACD -0.06 -0.07
Stochastic Oscillator 3.75 30.00

Price Performance

Historical Comparison
STAA
DVAX

About STAA STAAR Surgical Company

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: